drugset / Trial / NCT05294536

A Pharmacokinetic Study Comparing the Liraglutide Injection (RD12014) and Victoza® in Healthy Chinese Subjects

NCT05294536

Phase 1 Completed 50 enrolled Sunshine Lake Pharma Co., Ltd.
RandomizedCrossoverOpen-labelTreatment

Summary

To evaluate the pharmacokinetics similarity between the liraglutide injection (RD12014) produced by Sunshine Lake Pharma Co., Ltd. and liraglutide injection (Victoza®) produced by Novo Nordisk Pharmaceutical Co., Ltd for single dose in healthy male subjects, as well as to evaluate the similarity of the safety and immunogenicity between RD12014 and Victoza ® in healthy subjects.

Timeline

Start
2020-06-22
Primary completion
2020-07-20
Completion
2020-11-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Liraglutide Peptide 0.6 mg Subcutaneous